221 related articles for article (PubMed ID: 3471371)
1. CI-934, a new difluoroquinolone: in vitro antibacterial activity and proposed disk diffusion test interpretive criteria.
Fuchs PC; Barry AL; Jones RN; Thornsberry C; Ayers LW; Gavan TL; Gerlach EH
Diagn Microbiol Infect Dis; 1987 Mar; 6(3):185-92. PubMed ID: 3471371
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates.
Arpi M; Gahrn-Hansen B; Søgaard P; Bentzon MW
Acta Pathol Microbiol Immunol Scand B; 1987 Apr; 95(2):141-6. PubMed ID: 3473910
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of CI-934 compared with ciprofloxacin, enoxacin, norfloxacin, and vancomycin.
Floyd-Reising SA; Kelley SG; Hindler JA; Young LS
Diagn Microbiol Infect Dis; 1987 Apr; 6(4):301-6. PubMed ID: 3472704
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activity of amifloxacin and five other fluoroquinolone antimicrobial agents and preliminary criteria for the disk susceptibility test.
Barry AL; Jones RN
Eur J Clin Microbiol; 1987 Apr; 6(2):179-82. PubMed ID: 3474145
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones.
Chin NX; Novelli A; Neu HC
Antimicrob Agents Chemother; 1988 May; 32(5):656-62. PubMed ID: 3164987
[TBL] [Abstract][Full Text] [Related]
6. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
King A; Phillips I
J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
[TBL] [Abstract][Full Text] [Related]
7. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
Bassey CM; Baltch AL; Smith RP
J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
[TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of newer quinolones against aerobic bacteria.
Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
[TBL] [Abstract][Full Text] [Related]
9. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin.
Knapp JS; Hale JA; Neal SW; Wintersheid K; Rice RJ; Whittington WL
Antimicrob Agents Chemother; 1995 Nov; 39(11):2442-5. PubMed ID: 8585723
[TBL] [Abstract][Full Text] [Related]
10. RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteria.
Fuchs PC; Jones RN; Barry AL; Ayers LW; Gavan TL; Gerlach EH; Thornsberry C
Diagn Microbiol Infect Dis; 1987 May; 7(1):29-35. PubMed ID: 3121241
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility tests.
Barry AL; Jones RN; Thornsberry C; Ayers LW; Gavan TL; Gerlach EH
Eur J Clin Microbiol; 1986 Feb; 5(1):18-22. PubMed ID: 2938944
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of in vitro antibacterial activity of enoxacin: comparison with other orally absorbed antimicrobial agents, proposed disk diffusion test interpretive criteria, and quality control limits.
Fuchs PC; Barry AL; Jones RN; Thornsberry C
Diagn Microbiol Infect Dis; 1985 May; 3(3):213-21. PubMed ID: 3858044
[TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of A-56619 and A-56620, two new quinolones.
Barry AL; Thornsberry C; Jones RN
Antimicrob Agents Chemother; 1986 Jan; 29(1):40-3. PubMed ID: 2942099
[TBL] [Abstract][Full Text] [Related]
14. In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.
Smith SM
Antimicrob Agents Chemother; 1986 Feb; 29(2):325-6. PubMed ID: 2940966
[TBL] [Abstract][Full Text] [Related]
15. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.
King A; Shannon K; Phillips I
J Antimicrob Chemother; 1985 May; 15(5):551-8. PubMed ID: 3159712
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial activity of amifloxacin (WIN 49, 375), a new quinolone agent.
Neu HC; Labthavikul P
Diagn Microbiol Infect Dis; 1985 Nov; 3(6):469-78. PubMed ID: 4064609
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of trovafloxacin against ciprofloxacin-susceptible and -resistant clinical bacterial isolates and assessment of the trovafloxacin disk test.
Fuchs PC; Barry AL; Brown SD
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):33-8. PubMed ID: 9990473
[TBL] [Abstract][Full Text] [Related]
18. The comparative in-vitro activity of ofloxacin.
Grüneberg RN; Felmingham D; O'Hare MD; Robbins MJ; Perry K; Wall RA; Ridgway GL
J Antimicrob Chemother; 1988 Sep; 22 Suppl C():9-19. PubMed ID: 3182468
[TBL] [Abstract][Full Text] [Related]
19. In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis.
Berlin OG; Young LS; Bruckner DA
J Antimicrob Chemother; 1987 May; 19(5):611-5. PubMed ID: 3112095
[TBL] [Abstract][Full Text] [Related]
20. Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks.
Zerva L; Biedenbach DJ; Jones RN
J Clin Microbiol; 1996 Aug; 34(8):1970-4. PubMed ID: 8818892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
